Mohammad Azam, PhD

Rational polypharmacological targeting of FLT3, JAK2, ABL, and ERK1 suppresses the adaptive resistance to FLT3 inhibitors in AML. Azhar, M; Kincaid, Z; Kesarwani, M; Menke, J; Schwieterman, J; Ansari, S; Reaves, A; Ahmed, A; Shehzad, R; Khan, A; et al. Blood Advances. 2023; 7:1460-1476.

Momelotinib is a highly potent inhibitor of FLT3-mutant AML. Azhar, M; Kincaid, Z; Kesarwani, M; Ahmed, A; Wunderlich, M; Latif, T; Starczynowski, D; Azam, M. Blood Advances. 2022; 6:1186-1192.

PLaCatinG AML1-ETO. Azam, M. Blood. 2022; 139:959-961.

Adaptive responses to mTOR gene targeting in hematopoietic stem cells reveal a proliferative mechanism evasive to mTOR inhibition. Fan, C; Zhao, C; Zhang, F; Kesarwani, M; Tu, Z; Cai, X; Davis, AK; Xu, L; Hochstetler, CL; Chen, X; et al. Proceedings of the National Academy of Sciences of USA. 2021; 118:e2020102118.

SWATH-Proteomics of Ibrutinib's Action in Myeloid Leukemia Initiating Mutated G-CSFR Signaling. Dwivedi, P; Chutipongtanate, S; Muench, DE; Azam, M; Grimes, HL; Greis, KD. Proteomics: Clinical Applications. 2020; 14:e1900144.

Phospho serine and threonine analysis of normal and mutated granulocyte colony stimulating factor receptors. Dwivedi, P; Muench, DE; Wagner, M; Azam, M; Grimes, HL; Greis, KD. Scientific Data. 2019; 6:21.

Targeted Inhibition of the Dual Specificity Phosphatases DUSP1 and DUSP6 Suppress MPNST Growth via JNK. Ramkissoon, A; Chaney, KE; Milewski, D; Williams, KB; Williams, RL; Choi, K; Miller, A; Kalin, TV; Pressey, JG; Szabo, S; et al. Clinical Cancer Research. 2019; 25:4117-4127.

The high NRF2 expression confers chemotherapy resistance partly through up-regulated DUSP1 in myelodysplastic syndromes. Lin, P; Ren, Y; Yan, X; Luo, Y; Zhang, H; Kesarwani, M; Bu, J; Zhan, D; Zhou, Y; Tang, Y; et al. Haematologica: the hematology journal. 2019; 104:485-496.